$5.68
-0.04-0.7%
Last update: Nov 12, 4:05 PM
Myriad Genetics Inc
MYGNNASDAQ
Myriad Genetics fell 12.5% from $6.54 to $5.72, behind the S&P 500's +10.8%. Its worst day was Jul 31 (−46.7%), and its low came Jul 31 at $2.86.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Myriad Genetics closed at its highest level of the year, 20.9% above where the year started.
+2.3% · S&P 500 +0.9%
EPS of $0.04 beat the $-0.05 estimate on $209.8M revenue (est. $207.6M); Q1 revenue guidance of $200.0M–$203.0M against the $203.5M consensus.
Story events cover the past 12 months · Times ET
+1.1% · S&P 500 +0.7%
EPS of $-0.09 beat the $-0.09 estimate on $200.4M revenue (est. $202.5M); FY revenue guidance of $860.0M–$880.0M against the $865.7M consensus.
−18.3% · S&P 500 +1.4%
EPS of $-0.25 missed the $-0.06 estimate on $190.7M revenue (est. $205.9M); FY revenue guidance of $770.0M–$790.0M against the $862.7M consensus.
−46.7%, the year's worst day · S&P 500 +0.7%
Myriad Genetics shares rose 31.6%, while the S&P 500 rose 0.3%.
+31.6%, the year's best day, on 24M shares, the year's heaviest volume · S&P 500 +0.3%
EPS of $-0.11 beat the $-0.21 estimate on $202.7M revenue (est. $190.8M); FY revenue guidance of $780.0M–$790.0M against the $776.9M consensus.
+4.5% · S&P 500 −4.4%
Where it ended: a close of $5.72 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 22, 2027 (EPS est. $-0.25, revenue est. $192.6M).
Nothing in the past 12 months.
All MYGN dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MYGN and SPY from Benzinga historical bars. Not investment advice.
